Patents Examined by Donald E. Adams
  • Patent number: 5648469
    Abstract: Monoclonal antibodies have been produced which specifically bind to epitopes found in the cytoplasmic domain of the transferrin receptor (TR). The antibodies are useful for isolating sequences in a sample which contain TR cytoplasmic domain.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: July 15, 1997
    Assignee: The Salk Institute for Biological Studies
    Inventors: Ian S. Trowbridge, Suhaila N. White
  • Patent number: 5646254
    Abstract: Antibodies which react with the human phospholipase inhibitory protein/apolipoprotein AIV complex and hPIP are provided.
    Type: Grant
    Filed: April 26, 1994
    Date of Patent: July 8, 1997
    Assignee: Scios Nova Inc.
    Inventors: Lorin K. Johnson, John P. Longenecker
  • Patent number: 5644036
    Abstract: A purified preparation of an anti-CDW52 antibody which exhibits on size exclusion chromatography: a single peak under non-reducing conditions and two major peaks under reducing conditions.The preparation preferably also exhibits on conventional SDS PAGE: one main band using a non-reduced sample and two main bands using a reduced sample.Additionally the preparation exhibits on reversed phase HPLC: a single sharp peak under non-reducing conditions and two major peaks under reducing conditions. Also a process of purifying an anti-CDW52 antibody, formulations containing such a purified preparation and uses thereof.
    Type: Grant
    Filed: October 7, 1994
    Date of Patent: July 1, 1997
    Assignee: Burroughs Wellcome Company
    Inventors: Paul Ian Nicholas Ramage, Geoffrey Allen
  • Patent number: 5637300
    Abstract: Recombinant zona pellucidae proteins having altered, non-native glycosylation patterns are able to elicit the production of antibodies to matured zona pellucida proteins. Such recombinant proteins and the elicited antibodies can therefore be used in a contraceptive vaccine to prevent pregnancy in humans and animals.
    Type: Grant
    Filed: August 3, 1994
    Date of Patent: June 10, 1997
    Inventors: Bonnie S. Dunbar, Sarvamangala V. Prasad
  • Patent number: 5631158
    Abstract: Disclosed herein are improved methods and compositions for achieving enhanced protein production expressed from non-native gene constructs, including single chain sFv and derivative sequences. The methods and compositions are particularly useful for creating stably transfected, contitutively expressing immortalized mammalian cell lines that exhibit high recombinant protein productivity while maintaining a low copy number per cell of the non-native recombinant DNA sequence encoding the protein of interest.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: May 20, 1997
    Assignee: Creative BioMolecules, Inc.
    Inventors: Haimanti Dorai, Herrmann Oppermann
  • Patent number: 5626844
    Abstract: Monoclonal antibodies against the A chain of ricin have been found to be ective in protecting mammals from morbidity arising from exposure to ricin toxin. The neutralizing action of the antibodies does not appear to be mediated by complement or by immunoprecipitation. The antibodies of the invention are characterized as of isotype IgG1 having the binding characteristics which include: a) binding specifically to the neutralizing epitope of the ricin A chain and b) providing in vitro protection of at least 95% of EL-4 cells from 100 .eta.g/mL ricin challenge when said antibody is present in the tissue culture at a level of at least 1000 .eta.g/mL.
    Type: Grant
    Filed: December 27, 1994
    Date of Patent: May 6, 1997
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Paul V. Lemley, D. Craig Wright
  • Patent number: 5624804
    Abstract: The circulating advanced glycosylation endproducts Hb-AGE, serum AGE-peptides and urinary AGE-peptides are disclosed as long term markers of diseases and dysfunctions having as a characteristic the presence of a measurable difference in AGE concentration. Diagnostic and therapeutic protocols taking advantage of the characteristics of these AGEs are disclosed. Antibodies which recognize and bind to in vivo-derived advanced glycosylation endproducts are also disclosed. Methods of using these antibodies as well as pharmaceutical compositions are also disclosed, along with numerous diagnostic applications, including methods for the measurement of the presence and amount of advanced glycosylation endproducts in both plants and animals, including humans, as well as in cultivated and systhesized protein material for therapeutic use.
    Type: Grant
    Filed: October 1, 1992
    Date of Patent: April 29, 1997
    Assignee: The Rockefeller University
    Inventor: Richard J. Bucala
  • Patent number: 5624899
    Abstract: A novel hepatoma transmembrane kinase receptor ligand (Htk ligand) which binds to, and activates, the Htk receptor is disclosed. As examples, mouse and human Htk ligands have been identified in a variety of tissues using a soluble Htk-Fc fusion protein. The ligands have been cloned and sequenced. The invention also relates to nucleic acids encoding the ligand, methods for production and use of the ligand, and antibodies directed thereto.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: April 29, 1997
    Assignee: Genentech Inc.
    Inventors: Brian D. Bennett, William Matthews
  • Patent number: 5621083
    Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: April 15, 1997
    Assignee: XOMA Corporation
    Inventors: Marc D. Better, Stephen F. Carroll, Gary M. Studnicka
  • Patent number: 5614609
    Abstract: The present invention relates, in general, to a novel serine threonine kinase receptor, ALK-7. In particular, the present invention relates to nucleic acid molecules coding for ALK-7; ALK-7 polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to ALK-7; hybridomas containing the antibodies; nucleic acid probes for the detection of ALK-7 nucleic acid; a method of detecting ALK-7 nucleic acid or polypeptide in a sample; and kits containing nucleic acid probes or antibodies. This invention further relates to bioassays using the nucleic acid sequence, receptor protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with neurodegenerative disease. Therapeutic uses for ALK-7 are also provided. This invention also relates to ligands, agonists, and antagonists of the ALK-7 receptor, and diagnostic and therapeutic uses thereof.
    Type: Grant
    Filed: November 15, 1994
    Date of Patent: March 25, 1997
    Assignee: Carlos F. Ibanez
    Inventors: Carlos F. Ib a nez, Mikael Ryd en, Henrik J ornvall
  • Patent number: 5612458
    Abstract: This invention relates to antibodies to complexes formed between PNA (Peptide Nucleic Acid) and nucleic acids, particularly antibodies to PNA/DNA or PNA/RNA complexes. The preferred antibodies are polyclonal, monoclonal and recombinant antibodies that binds to PNA/DNA or PNA/RNA complexes, but not to single-stranded PNA, double-stranded nucleic acid or single-stranded nucleic acid. Peptide Nucleic Acids (PNA) are newly developed, not naturally occurring compounds comprising a polyamide backbone bearing a plurality of ligands such as naturally occuring nucleobases attached to a polyamide backbone through a suitable linker. PNA oligomers with a backbone of N-(2-aminoethyl)glycin units have a surprising high affinity for complementary nucleic acid forming very stable and specific complexes. This property makes PNA oligomers suitable as hybridization probes for detection of nucleic acids. The usability of PNA as hybridization probes is greatly increased by the present antibodies.
    Type: Grant
    Filed: December 22, 1994
    Date of Patent: March 18, 1997
    Assignee: Dako/AS
    Inventors: Jens J. Hyldig-Nielsen, Karl-Johan Pluzek
  • Patent number: 5612032
    Abstract: The subject invention relates to monoclonal antibodies and uses thereof. In particular, the invention relates to three monoclonal antibodies, referred to as B1, B3, and B5, which are useful in the treatment and diagnosis of many forms of cancer.
    Type: Grant
    Filed: December 22, 1994
    Date of Patent: March 18, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ira Pastan, Mark C. Willingham
  • Patent number: 5610279
    Abstract: The present invention is concerned with non-soluble proteins and soluble or insoluble fragments thereof, which bind TNF, in homogeneous form, as well as their physiologically compatible salts, especially those proteins having a molecular weight of about 55 or 75 kD (non-reducing SDS-PAGE conditions), a process for the isolation of such proteins, antibodies against such proteins, DNA sequences which code for non-soluble proteins and soluble or non-soluble fragments thereof, which bind TNF, as well as those which code for proteins comprising partly of a soluble fragment, which binds TNF, and partly of all domains except the first of the constant region of the heavy chain of human immunoglobulins and the recombinant proteins coded thereby as well as a process for their manufacture using transformed pro- and eukaryotic host cells.
    Type: Grant
    Filed: July 21, 1993
    Date of Patent: March 11, 1997
    Assignee: Hoffman-La Roche Inc.
    Inventors: Manfred Brockhaus, Zlatko Dembic, Reiner Gentz, Werner Lesslauer, Hansruedi Lotscher, Ernst-Jurgen Schlaeger
  • Patent number: 5610280
    Abstract: The present invention provides a human monoclonal antibody against melanoma, characterized in that it binds to the gangliosides GM3 and GD3 but essentially does not bind to the gangliosides GM1, GM2, GD1a, GD1b and GD2, the binding of the antibody to the gangliosides having been determined by immune staining after thin layer chromatographic separation of the gangliosides. The present invention also provides a process for the production of human monoclonal antibodies directed against melanoma, wherein, without previous immunization, B-lymphocytes are isolated from a healthy person, the isolated B-lymphocytes are immortalized, antibodies from the immortalized B-lymphocytes are screened by immune-histochemical analysis for binding against melanoma and/or melanoma metastases, the positively reacting B-lymphocytes are selected, cultured and monoclonal antibodies obtained therefrom.
    Type: Grant
    Filed: March 15, 1994
    Date of Patent: March 11, 1997
    Assignee: Boehringer Mannheim GmbH
    Inventors: Michael Brandt, Josef Endl, Herbert Jungfer, Winfried Albert
  • Patent number: 5608039
    Abstract: This invention provides for recombinant single chain antibodies capable of specifically binding to a Lewis.sup.Y -related carbohydrate antigen and fusion proteins comprising these antibodies. More particularly, the invention provides for single chain Fv regions of the monoclonal antibody B3. The invention also provides for a method of improving the binding affinity of antibodies lacking a serine at position 95 of the V.sub.H region that involves mutating position 95 to a serine.
    Type: Grant
    Filed: October 28, 1994
    Date of Patent: March 4, 1997
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Ira Pastan, Mark Willingham, David Fitzgerald, Ulrich Brinkmann, Lee Pai
  • Patent number: 5602027
    Abstract: A new cell line TriH8 is obtained by fusing a particular sub-clone, A431c, of the human epidermoid carcinoma cell line A431 with the TOS/H8 (human/human) hybridoma. Fused cell TriH8 has been deposited under FRI accession number FERM BP-4452. The fused cell is capable of proliferating in basal medium without addition of serum or growth factor. The cell line is more effective in producing antibody (IgM) than the donor cell TOS/H8.
    Type: Grant
    Filed: December 16, 1992
    Date of Patent: February 11, 1997
    Assignee: Yoshihide Hagiwara
    Inventors: Hideaki Hagiwara, Hideo Yuasa
  • Patent number: 5597567
    Abstract: The present invention relates, in general, to a method of blocking of cell adhesion molecules. In particular, the present invention relates to a method of blocking cell adhesion molecules with monoclonal antibodies or synthesized substances.
    Type: Grant
    Filed: February 4, 1994
    Date of Patent: January 28, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Scott M. Whitcup, Chi-Chao Chan, Robert B. Nussenblatt
  • Patent number: 5597725
    Abstract: DNA sequences encoding novel cadherins, desginated cadherins-4 through -12, are disclosed along with methods and materials for the recombinant production of the same. Antibody substances specific for the novel cadherins and cadherin peptides are disclosed as useful for modulating the natural binding and/or regulatory activities of the cadherins.
    Type: Grant
    Filed: January 26, 1994
    Date of Patent: January 28, 1997
    Assignee: Doheny Eye Institute
    Inventor: Shintaro Suzuki
  • Patent number: 5589573
    Abstract: Amino acid sequences of the H chain and L chain variable regions of mouse monoclonal antibodies Idio 3, Idio 17, Idio 20, Idio 27 and Idio 33 against idiotypes of a cancer cell antigen-specific human immunoglobulin CLN/IgG produced by a human/human fused cell strain CLN/SUZ H11, and base sequences of the genes of the variable regions are disclosed. The above amino acid sequences and the base sequences are useful in medical and pharmaceutical fields such as prophylaxis, treatment and/or diagnosis of human diseases, and/or in pharmacological and/or biochemical fields, etc. such as biochemical reagents, and reagents for purification of biomacromolecules.
    Type: Grant
    Filed: October 6, 1994
    Date of Patent: December 31, 1996
    Assignee: Yoshihide Hagiwara
    Inventors: Hideaki Hagiwara, Yasuyuki Aotsuka
  • Patent number: 5587458
    Abstract: The present invention relates to novel antibodies, in particular monoclonal and single chain antibodies derived therefrom which specifically bind to erbB-2, as well as diagnostic and therapeutic uses thereof. The present invention also relates to a combination of at least two erbB-2 specific antibodies which are capable of preventing and treating human malignancies wherein the malignant cells overexpress gp185.sup.erbB-2. The monoclonal antibodies of the combination preferably recognize different epitopes of the gp185 expression product of erbB-2, therefore, the antibodies do not cross react with each other. Preferably, the combination will provide for synergistic decrease in the expression of the erbB-2 gene product.
    Type: Grant
    Filed: May 14, 1993
    Date of Patent: December 24, 1996
    Assignee: Aronex Pharmaceuticals, Inc.
    Inventors: C. Richter King, Philip G. Kasprzyk, Robert E. Bird